Geometric Mean Fold Rise (GMFR) of Serum bAb Against SARS-CoV-2 on Day 57;Geometric Mean Titers (GMT) of Serum binding antibody (bAb) Against SARS-CoV-2 on Day 57;Percentage of Participants with Any AE Leading to Discontinuation of Vaccination;Percentage of Participants with Any AE Leading to Participant's Withdrawal from the Trial until Day 57;Percentage of Participants with Medically-Attended Adverse Events (MAAEs) until Day 57;Percentage of Participants with Reported Solicited Local Adverse Events (AEs) for 7 Days Following Each Vaccination;Percentage of Participants with SARS-CoV-2 Infection until Day 57;Percentage of Participants with Serious AE (SAE) until Day 57;Percentage of Participants with Solicited Systemic AEs for 7 Days Following Each Vaccination;Percentage of Participants with Unsolicited AEs for 28 Days After Each Vaccination;Seroconversion Rate (SCR) of Serum bAb Against SARS-CoV-2 on Day 57

Geometric Mean Fold Rise (GMFR) of Serum bAb Against SARS-CoV-2 on Day 57;Geometric Mean Titers (GMT) of Serum binding antibody (bAb) Against SARS-CoV-2 on Day 57;Percentage of Participants with Any AE Leading to Discontinuation of Vaccination;Percentage of Participants with Any AE Leading to Participant's Withdrawal from the Trial until Day 57;Percentage of Participants with Medically-Attended Adverse Events (MAAEs) until Day 57;Percentage of Participants with Reported Solicited Local Adverse Events (AEs) for 7 Days Following Each Vaccination;Percentage of Participants with SARS-CoV-2 Infection until Day 57;Percentage of Participants with Serious AE (SAE) until Day 57;Percentage of Participants with Solicited Systemic AEs for 7 Days Following Each Vaccination;Percentage of Participants with Unsolicited AEs for 28 Days After Each Vaccination;Seroconversion Rate (SCR) of Serum bAb Against SARS-CoV-2 on Day 57